Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 19/20 | 0.44 |
| ▸ | NQO2 | P16083 | 2/20 | 0.37 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | PLG | P00747 | 1/20 | 0.37 |
| ▸ | PLAT | P00750 | 1/20 | 0.37 |
| ▸ | PROC | P04070 | 1/20 | 0.37 |
| ▸ | HPN | P05981 | 1/20 | 0.37 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.37 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.37 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.37 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7120809 | 0.92 | F2 (0.47) | F2NQO2SLC22A2F10PLG | |
| SCHEMBL7120120 | 0.89 | F2 (0.51) | F2NQO2SLC22A2F10PLG | |
| SCHEMBL7121489 | 0.88 | F2 (0.48) | F2NQO2SLC22A2F10PLG | |
| SCHEMBL7124480 | 0.87 | F2 (0.50) | F2NQO2SLC22A2F10PLG | |
| SCHEMBL7118131 | 0.86 | F2 (0.46) | F2NQO2SLC22A2F10PLG | |
| SCHEMBL7119763 | 0.86 | F2 (0.46) | F2NQO2SLC22A2F10PLG | |
| SCHEMBL7223673 | 0.86 | F2 (0.39) | F2 | |
| SCHEMBL7121452 | 0.85 | F2 (0.46) | F2NQO2SLC22A2F10PLG | |
| SCHEMBL7118128 | 0.84 | F2 (0.49) | F2NQO2SLC22A2F10PLG | |
| SCHEMBL7117072 | 0.84 | F2 (0.46) | F2NQO2SLC22A2F10PLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6656956-B2 | Tryptase inhibitor; antiinflamamtory agents, antiallergens | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-12-02 | — | — | US | claimed |
| US-20030105137-A1 | Benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-06-05 | — | — | US | claimed |
| US-6656956-B2 | Tryptase inhibitor; antiinflamamtory agents, antiallergens | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105137-A1 | Benzimidazole derivatives, processes for preparing them and their use as pharmaceutical compositions | CMA1, TPSD1, TPSAB1 | F2 764/4885NQO2 489/4885SLC22A2 4372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.